ASSOCIATION FOR ACCESSIBLE MEDICINES lobbying for ASSOCIATION FOR ACCESSIBLE MEDICINES

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 17, 2026

Expenses

$770,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

PHILLIP HARBISON New on this filing

Previously held: Legislative Director / Sr. Policy Advisor / Legislative Assistant, Rep. Morgan Griffith; Legislative Assistant / Special Projects Coordinator, Rep. David McKinley

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 10

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Medicare/Medicaid

Medicare Part D Reform. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. CMS RFC on Domestic Manufacturing. CMS Final Rule on Bona Fide Service Fees. HCPCS Codes. Tiering. PBM Bid Transparency.

Pharmacy

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Copyright/Patent/Trademark

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Trade (domestic/foreign)

General Trade Issues. Drug Supply Chain. Rules of Origin. Country of Origin Labeling. Tariffs on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars. India Trade Negotiations. United States-Mexico-Canada Agreement. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act.

Bills named in this filing 24

H.R. 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S. 1302
Increasing Transparency in Generic Drug Applications Act
H.R. 4191
MAPS Act
S. 1784
MAPS Act
H.R. 4132
Prescription Information Modernization Act of 2025
S. 2027
Prescription Information Modernization Act of 2025
S. 1414
Expedited Access to Biosimilars Act
H.R. 9661
Expedited Access to Biosimilars Act
S. 3469
BIOSECURE Act of 2025
H.R. 8269
CLEAR LABELS Act
S. 3788
CLEAR LABELS Act
S. 4280
SAFE Act
H.R. 3160
PREVAIL Act
S. 1553
PREVAIL Act
H.R. 3152
Patent Eligibility Restoration Act of 2025
S. 1546
Patent Eligibility Restoration Act of 2025
H.R. 3269
ETHIC Act
S. 2276
ETHIC Act
S. 2658
Medication Affordability and Patent Integrity Act
S. 1041
Affordable Prescriptions for Patients Act
S. 1096
Preserve Access to Affordable Generics and Biosimilars Act
H.R. 6485
Skinny Labels, Big Savings Act
S. 43
Skinny Labels, Big Savings Act
H.R. 5811
Restoring America’s Leadership in Innovation Act of 2025